All Posts

Frequent nighttime urination, weak urine flow, and a feeling of incomplete emptying are common issues among middle-aged and older men, often linked to benign prostatic hyperplasia (BPH). This age-related condition affects quality of life but is manageable with lifestyle adjustments, medication, or minimally invasive surgery. If you experience persistent urinary discomfort, avoid self-diagnosis. Seek professional urological examination for timely and appropriate care.

Shanghai, July 6, 2026 — Jiahui International Cancer Center (JICC) announced that a 59-year-old male patient from New Zealand has successfully finished T-cell apheresis for Satricabtagene autoleucel (CT041). This marks the first international patient to complete T-cell collection in China for the world’s first approved solid tumor CAR-T therapy, demonstrating China’s global competitiveness in translational cell therapy and showcasing Chinese innovative treatments to global pa

Independently developed by Sichuan Biokin Pharmaceutical Co., Ltd., Izalontamab Brengitecan for Injection (Iza-Bren) is a first-in-class EGFR×HER3 bispecific antibody-drug conjugate (bispecific ADC). It received its first NMPA approval in June 2026 for adult patients with recurrent/metastatic nasopharyngeal carcinoma who failed at least two lines of systemic chemotherapy plus PD-1/PD-L1 inhibitors, and previously obtained FDA Breakthrough Therapy Designation.

The earliest pivotal CAR-T trial for R/R DLBCL, utilizing CD19-targeted CAR-T with CD28 costimulatory domain. The ZUMA series has advanced to ZUMA 9 and real-world research, enrolling over 295 patients. Key findings: CD28-based CAR-T triggers rapid, severe cytokine release syndrome (CRS); 32% of patients required ICU admission for CRS. Re-administering identical CAR-T cells to partial response (PR) patients fails to boost efficacy.

Genetic testing is indispensable for hematological disease management. For acute leukemia, it supports diagnosis, prognosis assessment and treatment guidance. However, interpreting genetic mutation reports is highly complex. Clinicians must distinguish germline (inherited) mutations from somatic tumor-derived variants, clarify whether germline variants contribute to leukemia susceptibility, analyze mutation loci, variant combinations, and their impacts on prognosis and target

Genetic testing plays a vital role in diagnosing and treating hematologic malignancies. It enables precise disease classification, prognostic stratification, and personalized treatment planning, guiding targeted therapies and minimizing adverse reactions. By detecting gene mutations and monitoring minimal residual disease (MRD), it helps assess relapse risks and improve patient outcomes.

MICM integrated diagnosis covers Morphology (M), Immunology (I), Cytogenetics (C) and Molecular biology (M), serving as the core diagnostic system for hematological malignancies. Its updated scope also incorporates two additional P modules: Pathogen detection and Pharmacogenomics (MICM-PP). Director Tong Chunrong from Beijing Boren Hospital elaborates on how this integrated system enables precise subtyping and individualized therapy for blood cancers.

A Brain-Computer Interface (BCI) is a direct communication pathway between the human brain's neural signals and an external device or computer. Implantable BCI involves surgically placing microelectrode arrays directly onto or within the cortex, enabling high-resolution, real-time decoding of neural intent. This precision unlocks capabilities previously confined to science fiction: patients with complete paralysis can control computers, robotic limbs, or even stimulate their

Wondering why leukemia patients need genetic testing? Director Zheng Qinlong explains its vital role in precision hematology care. Genetic heterogeneity drives varied chemo responses; gene sequencing guides targeted therapy, MRD surveillance and risk stratification. Comprehensive molecular profiling avoids ineffective regimens, cuts costs and enables personalized long-term treatment plans.

Clinical evaluations are systematically carried out centered on five core laboratory divisions (naming varies across hospitals): Cell Morphology Laboratory, Pathological Diagnosis Laboratory, Flow Cytometry Laboratory, Cytogenetics Laboratory, and Molecular Diagnosis Laboratory. Corresponding tests include cell morphology and cytochemical staining, pathology and immunohistochemistry, flow cytometry, karyotype analysis, FISH, gene testing, etc.

In traditional oncology, the "trial-and-error" method has long been a frustrating reality for patients. Clinicians prescribe standard chemotherapy and targeted regimens based on global guidelines.Today, a revolutionary technology known as Organoid Drug Sensitivity Testing is dismantling this paradigm. By cultivating a patient's micro-scale "biological avatar" in the laboratory, clinicians can pre-screen and predict the most effective drug combination before administration.

Many patients wonder: How long can CAR-T therapy last? Its long-term efficacy depends not only on the initial anti-tumor effect but also on the persistence of CAR-T cells in the body. Factors like T-cell quality, production process, tumor immune escape, and standardized whole-process management all affect outcomes. To improve durability, doctors recommend early intervention, optimized cell preparation, personalized targets, and long-term monitoring.

A Malaysian patient Hana flew over 3,000km from Kuala Lumpur to Xi’an for thyroid cancer surgery at Hygeia Chang’an Hospital. Professor Liu’s team removed her tumor with minimal blood loss under 10ml while protecting nerve functions. Cross-department MDT experts customized long-term recovery plans. Full one-stop international care and warm nursing made her overseas treatment a wonderful experience.

The world’s first China-developed bone adhesive Bone 02 has earned dual recognition from China’s NMPA Innovative Medical Device pathway and U.S. FDA Breakthrough Device Designation. This revolutionary biomaterial bonds broken bones in wet, bloody conditions and gradually degrades as new bone forms, replacing traditional metal screws with less trauma and faster healing. With over 150 patients in clinical trials, it has shown excellent results in fracture repair, spinal fusion

A major new medical policy has arrived! Personalized mRNA cancer vaccines are now available for 6 types of digestive system tumors, including pancreatic, liver, gastric, and colorectal cancer. This tailored vaccine trains your immune system to target residual cancer cells, greatly lowering recurrence risk and extending survival. Important: eligibility must be confirmed BEFORE surgery, as fresh tumor tissue is required for vaccine development. Don’t miss this life-changing opp

MedTourChina Joins the YRD International Medical and Special Services Alliance! Exciting milestone! MedTourChina has officially joined the Yangtze River Delta (YRD) International Medical and Special Services Alliance. By integrating with top-tier healthcare resources across Shanghai and Hangzhou, we are further strengthening our ability to provide world-class, seamless medical services to international patients—from cross-border coordination to direct billing.

China’s first foreign patient treated with axicabtagene ciloleucel CAR-T therapy has been discharged from Shanghai Jiahui International Hospital. A Singaporean mother with refractory lymphoma chose Jiahui for its world-class care, shorter wait and lower cost vs Western countries. Supported by a full MDT team, she recovered smoothly, marking a milestone for China’s international CAR-T treatment.

The world’s first CAR-T therapy for solid tumors, Kailimei® (CT041), has been approved in China for advanced gastric cancer. A milestone breakthrough, it marks China’s leap from follower to leader in solid tumor cell therapy. Jiahui International Cancer Center is among the first to offer this innovative treatment, bringing new hope to patients.

How a Pakistani DLBCL patient went from palliative care to remission with CAR-T therapy at Jiahui International Hospital in Shanghai. Real story, costs, and visa guide.

In the realm of advanced hepatobiliary oncology, a diagnosis of locally advanced, unresectable cholangiocarcinoma—especially with major vascular involvement—has historically been considered a clinical "dead end." However, a recent case from Sir Run Run Shaw Hospital (SRRSH) is challenging this status quo, demonstrating how a "Conversion Therapy" paradigm can successfully redefine treatment boundaries.